NFKBIA and breast cancer: In TMD-231 breast cancer cells, treatment with compound 32 reduced the DNA-binding activity of NF-κB through inhibition of IKK-β-mediated p65 phosphorylation and caused elevation of basal IkBa levels through inhibition of constitutive IkBa turnover and NF-κB activation.